Physician profile
Samer Roy
NPI 1871501338
$4,143.89
in general payments reported to CMS, 2019-2025
29 companies · $596 in 2025
The $596 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $426 · 2021: $444 · 2022: $537 · 2023: $648 · 2024: $542 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,772 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,771.99 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $940.62 | 2021-2025 | Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $566.85 | 2022-2025 | |
| Novo Nordisk INC | $405.43 | 2019-2025 | Rybelsus, Ozempic |
| Amgen INC. | $341.36 | 2019-2023 | Evenity |
| Allergan, INC. | $295.64 | 2019-2020 | |
| Lilly USA, LLC | $293.28 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.52 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Janssen Pharmaceuticals, INC | $102.81 | 2019-2021 | |
| Glaxosmithkline, LLC. | $88.21 | 2019-2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $80.78 | 2019-2022 | |
| Pfizer INC. | $75.65 | 2019-2025 | |
| Ultragenyx Pharmaceutical INC. | $75.19 | 2023-2024 | Crysvita |
| Kyowa Kirin, INC. | $74.93 | 2024 | Crysvita |
| Eisai INC. | $67.31 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $58.69 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $57.81 | 2023-2025 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $54.07 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $46.68 | 2020-2024 | |
| Boston Scientific Corporation | $34.88 | 2023 | Watchman Flx |
| Philips North America LLC | $30.84 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.74 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.86 | 2025 | Caplyta |
| Viiv Healthcare Company | $22.27 | 2025 | Cabenuva |
| Abbott Laboratories | $21.40 | 2021 | |
| Evoke Pharma, INC. | $20.24 | 2025 | |
| Alnylam Pharmaceuticals INC. | $16.74 | 2022 | |
| Corcept Therapeutics | $16.62 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.87 | 2019 | |
| Grifols USA, LLC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.